NewcelX Ltd.

NewcelX Ltd. announced a private placement financing, entering into securities purchase agreements with accredited investors to raise $1.55 million in gross proceeds. The financing involves the sale of common shares and common warrants. The company intends to use the net proceeds, along with its current cash and a previously announced equity line, primarily to advance its lead program NCEL-101 for type 1 diabetes, including initiating FDA-required toxicology studies, enhancing cell manufacturing, and preparing for a Phase 1/2a clinical trial in 2027. The offering is anticipated to close on or about November 23, 2026.

NewcelX Ltd. announced the pricing of a $1.55 million private placement equity financing. The shares were sold at a 20% premium to the market price, indicating strong investor confidence. The funds raised will be used to advance the company's lead program, NCEL-101, for type 1 diabetes, including initiating FDA-required studies and preparing for Phase 1/2a clinical trials. The financing was led by international healthcare investors and The Crushing T1 Foundation.

NewcelX Ltd. announced a private placement financing with certain accredited investors, expecting to raise $1.4 million in gross proceeds. The offering includes the sale of 347,134 common shares or pre-funded warrants at $4.033 per share, along with common warrants that could generate an additional $1.5 million upon full exercise. The company intends to use the net proceeds to advance its lead program, NCEL-101 for Type 1 Diabetes, in collaboration with Eledon Pharmaceuticals, and for general corporate purposes. The closing is anticipated around August 14, 2026.

NewcelX Ltd. announced it has secured $1.4 million in equity financing through a private placement. The shares were priced at $4.033 per share, representing a 20% premium to the last closing price, reflecting strong investor confidence. The proceeds will primarily be used to advance NCEL-101, the company's lead program for type 1 diabetes, following a successful FDA Pre-IND meeting, as well as for working capital and general corporate purposes.

NewcelX Ltd. announced a private placement of 347,134 common shares at $4.033 per share, representing a 20% premium to its last closing price. The offering also includes warrants to purchase an equal number of shares at an exercise price of $4.437 per share. Participation from existing shareholders and new investors reflects confidence in the company's strategy and its lead program, NCEL-101. The company intends to use the net proceeds to advance NCEL-101 towards IND-enabling studies and for general corporate purposes, with the closing expected around August 14, 2026.

NewcelX Ltd. announced that the Brazilian Patent and Trademark Office has issued a patent for its innovative cell selection and enrichment technology, protecting the manufacturing process of its lead clinical compound, NCEL-101, until November 2036. This patent expands the company's global intellectual property portfolio, strengthening its position in the strategically important Brazilian Type 1 Diabetes market, which has approximately 500,000 patients. The grant follows a successful FDA Type B Pre-IND meeting for NCEL-101, paving the way for clinical trials.

NewcelX Ltd. announced the appointment of Dr. Camillo Ricordi, a globally recognized authority in diabetes cure-focused research and cellular transplantation, to its Scientific Advisory Board. This strategic addition follows the company's successful FDA Type B Pre-IND meeting for NCEL-101, which established a clear regulatory pathway for clinical trials. Dr. Ricordi will provide invaluable expertise to advance NewcelX's Type 1 Diabetes program and its collaboration with Eledon Pharmaceuticals, strengthening the company's scientific leadership.

NewcelX Ltd. announced the successful completion of its Type B Pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (FDA) for NCEL-101. The FDA provided constructive feedback and alignment on the company's proposed development strategy, offering a clear regulatory path toward initiating clinical trials for type 1 diabetes. This milestone supports NewcelX's plan to combine NCEL-101 with Eledon Pharmaceuticals' tegoprubart, an investigational immunomodulatory agent, aiming for a potential functional cure for type 1 diabetes. The FDA's favorable feedback on CMC processes and preclinical programs allows NewcelX to proceed with IND-enabling activities.

NewcelX announced the successful completion of its Type B Pre-IND meeting with the U.S. FDA for its lead candidate, NCEL-101, for type 1 diabetes. The FDA provided constructive feedback and alignment on the company's development strategy, offering clarity on the regulatory pathway for a clinical trial. This represents a significant milestone toward clinical development of NCEL-101, which will be combined with Eledon Pharmaceuticals' tegoprubart.

NewcelX Ltd. convened its Annual General Shareholders’ Meeting on June 30, 2026. During the meeting, the company's shareholders approved all proposals that were presented. These proposals had been previously described in a Form 6-K furnished to the SEC on June 5, 2026.